Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASHLAND INC.ASH · Entity 4139 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASHLAND INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,407 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 212 · Balance 2,407 F1: 1 for 1. F2: Common Stock Units acquired pursuant to Ashland's Deferred Compensation Plan for Non-Employee Directors (the "Plan") and exempt under Rule 16b-3. (One (1) Common Stock Unit in the Plan is the equivalent of one (1) share of Ashland Common Stock.) F3: Subject to any deferral election on timing of distribution by the reporting person under the Plan, the Common Stock Units are payable in Common Stock upon the reporting person's separation from service as a director. F4: Balance includes additional Common Stock Units acquired in lieu of cash dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: 1 for 1.
F2: Common Stock Units acquired pursuant to Ashland's Deferred Compensation Plan for Non-Employee Directors (the "Plan") and exempt under Rule 16b-3. (One (1) Common Stock Unit in the Plan is the equivalent of one (1) share of Ashland Common Stock.)
F3: Subject to any deferral election on timing of distribution by the reporting person under the Plan, the Common Stock Units are payable in Common Stock upon the reporting person's separation from service as a director.
F4: Balance includes additional Common Stock Units acquired in lieu of cash dividends.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date April 29, 2026 · Filed May 01, 2026
Section 16 reporting ended · disclosed 2026-05-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,347 |
Ending reported balance
After 2026-04-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-29 · Exercise / conversion · Acquired 2,597 · Balance 16,477 Row 2 · 2026-04-29 · Tax withholding · Disposed 1,130 · Balance 15,347 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2028-04-29 | Direct | 5,194 |
Reported balance
After 2026-04-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-29 · Exercise / conversion · Disposed 2,597 · Balance 5,194 F4: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT April 2025 | 74,289 |
Reported balance
Holding disclosure · report date 2026-04-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 74,289 F1: The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay April 2025 Grantor Retained Annuity Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT August 2025 | 57,622 |
Reported balance
Holding disclosure · report date 2026-04-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 57,622 F2: The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay August 2025 Grantor Retained Annuity Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT February 2025 | 53,417 |
Reported balance
Holding disclosure · report date 2026-04-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 53,417 F3: The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay February 2025 Grantor Retained Annuity Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay April 2025 Grantor Retained Annuity Trust.
F2: The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay August 2025 Grantor Retained Annuity Trust.
F3: The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay February 2025 Grantor Retained Annuity Trust.
F4: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F5: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2021 Filed Nov 2, 2021 22:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 24,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028167 · form4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,764.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 85,714 | $0.00 Strike: $75.99 | $0.00 |
DisclosureSEC source: 0001127602-21-015747 · form4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,714 Underlying: Common Stock · 85,714 shares Expires 2031-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 25,772 | $72.62 | $1,871,562.64 |
DisclosureSEC source: 0001127602-21-008571 · form4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,145.357 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 22:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 10,380 | $83.01 | $861,675.98 |
DisclosureSEC source: 0001127602-20-023725 · form4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,373.357 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.05, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 84,576 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001127602-20-015439 · form4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,576 Underlying: Common Stock · 84,576 shares Expires 2030-04-30 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 15,785 | $76.56 | $1,208,499.60 |
DisclosureSEC source: 0001127602-20-009126 · form4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,632.08 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 64,922 | $0.00 Strike: $80.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027578 · a4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,922 Underlying: Common Stock · 64,922 shares Expires 2029-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 10,380 | $80.38 | $834,344.40 |
DisclosureSEC source: 0001225208-19-003889 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,847.08 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 29,851 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-19-002568 · doc4.xml · derivative · entry 5 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,851 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 43,876 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-002568 · doc4.xml · derivative · entry 4 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,876 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 73,727 | $78.62 | $5,796,306.15 |
DisclosureSEC source: 0001225208-19-002568 · doc4.xml · nonDerivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,467.08 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.5700 to $78.6900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 29,851 | $36.56 | $1,091,352.56 |
DisclosureSEC source: 0001225208-19-002568 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,194.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 43,876 | $39.29 | $1,723,888.04 |
DisclosureSEC source: 0001225208-19-002568 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,343.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 19,208 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · derivative · entry 5 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,208 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · derivative · entry 4 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 2/19/2011, 2/19/2012 and 2/19/2013. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 29,208 | $65.20 | $1,904,361.60 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · nonDerivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,467.08 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 10,000 | $37.49 | $374,900.00 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,675.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,208 | $33.49 | $643,275.92 |
DisclosureSEC source: 0001225208-18-012336 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,675.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 65,872 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008932 · doc4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,872 Underlying: Common Stock · 65,872 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,009 | $58.87 | $236,009.83 |
DisclosureSEC source: 0001225208-18-008420 · doc4.xml · derivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,009 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,142 | $58.87 | $67,229.54 |
DisclosureSEC source: 0001225208-18-008420 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,467.08 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008420 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,609.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 4,522 | $54.72 | $247,443.84 |
DisclosureSEC source: 0001225208-18-005014 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,181.926 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 19:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | OtherPhantom Stock · Derivative | 13,099.521 | $56.21 | $736,324.08 |
DisclosureSEC source: 0001225208-17-017206 · doc4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,122.638 Underlying: Common Stock · 13,099.521 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck common stock and was granted under the Merck & Co., Inc. Deferral Program (the "Program"). The Program includes the right of redesignation to other investment measures within the Program. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck common stock and was granted under the Merck & Co., Inc. Deferral Program (the "Program"). The Program includes the right of redesignation to other investment measures within the Program. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck common stock and was granted under the Merck & Co., Inc. Deferral Program (the "Program"). The Program includes the right of redesignation to other investment measures within the Program. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 64,194 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009431 · doc4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,194 Underlying: Common Stock · 64,194 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 3,092 | $62.38 | $192,878.96 |
DisclosureSEC source: 0001225208-17-008904 · doc4.xml · derivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,092 shares Expires 2017-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 974 | $62.38 | $60,758.12 |
DisclosureSEC source: 0001225208-17-008904 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,662.548 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2017 Filed May 3, 2017 13:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-008904 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,636.548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,758 | $65.85 | $247,464.30 |
DisclosureSEC source: 0001225208-17-005082 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,245.635 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 02, 2016 Filed Aug 3, 2016 18:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 5,150 | $58.66 | $302,099.00 |
DisclosureSEC source: 0001225208-16-037428 · doc4.xml · derivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,150 shares Expires 2016-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| August 02, 2016 Filed Aug 3, 2016 18:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,619 | $58.66 | $94,970.54 |
DisclosureSEC source: 0001225208-16-037428 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,951.247 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 02, 2016 Filed Aug 3, 2016 18:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-037428 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,570.247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 81,494 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033203 · doc4.xml · derivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,494 Underlying: Common Stock · 81,494 shares Expires 2026-05-09 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,002 | $54.09 | $216,468.18 |
DisclosureSEC source: 0001225208-16-032903 · doc4.xml · derivative · entry 3 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,002 shares Expires 2016-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,258 | $54.09 | $68,045.22 |
DisclosureSEC source: 0001225208-16-032903 · doc4.xml · nonDerivative · entry 2 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,171.795 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:20 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-032903 · doc4.xml · nonDerivative · entry 1 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,429.795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.